Chinese authorities this Friday approved the emergency use of the Sinovac vaccine against COVID-19 in children between the ages of three and 17, pharmaceutical company president Yin Weidong told the media.
However, Yin has admitted that “it has not yet been decided when the vaccine will be used” and it has not been specified from which age group he will be vaccinated, reports the Chinese newspaper “Global Times”.
Sinovac has completed the Phase I and II clinical research phase that involved several hundred volunteers in this age group, which has shown that the vaccine is “as safe and effective as it is for adults,” he said. Yin to China Central Television (CCTV) in an interview.
The drug regulatory agency in Nepal this Friday approved the emergency use of the Chinese COVID-19 vaccine, according to the Nepalese media “The Kathmandu Post”. This makes Nepal the 48th country in the region to have approved its use.
To date, pharmaceutical company Sinovac has shipped more than 600 million doses to nearly 40 countries and regions around the world, including China, and last Wednesday the WHO approved its emergency use.